Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

430 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M. Comi G, et al. Among authors: boyko a. Mult Scler. 2022 Apr;28(4):608-619. doi: 10.1177/13524585211032803. Epub 2021 Aug 11. Mult Scler. 2022. PMID: 34378456 Clinical Trial.
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5063 Study Group. Comi G, et al. Among authors: boyko a. Mult Scler. 2010 Nov;16(11):1360-6. doi: 10.1177/1352458510378127. Epub 2010 Sep 8. Mult Scler. 2010. PMID: 20834039 Clinical Trial.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO Study Group. Comi G, et al. Among authors: boyko a. N Engl J Med. 2012 Mar 15;366(11):1000-9. doi: 10.1056/NEJMoa1104318. N Engl J Med. 2012. PMID: 22417253 Free article. Clinical Trial.
The management of multiple sclerosis in children: a European view.
Ghezzi A, Banwell B, Boyko A, Amato MP, Anlar B, Blinkenberg M, Boon M, Filippi M, Jozwiak S, Ketelslegers I, Kornek B, Lim M, Lindstrom E, Nadj C, Neuteboom R, Rocca MA, Rostasy K, Tardieu M, Wassmer E, Catsman-Berrevoets C, Hintzen R. Ghezzi A, et al. Among authors: boyko a. Mult Scler. 2010 Oct;16(10):1258-67. doi: 10.1177/1352458510375568. Epub 2010 Aug 4. Mult Scler. 2010. PMID: 20685764
International consensus on quality standards for brain health-focused care in multiple sclerosis.
Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G. Hobart J, et al. Among authors: boyko a. Mult Scler. 2019 Nov;25(13):1809-1818. doi: 10.1177/1352458518809326. Epub 2018 Nov 1. Mult Scler. 2019. PMID: 30381987 Free PMC article.
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, Kolodny S, Zivadinov R. Khan O, et al. Among authors: boyko a. Mult Scler. 2017 May;23(6):818-829. doi: 10.1177/1352458516664033. Epub 2016 Aug 8. Mult Scler. 2017. PMID: 27503905 Clinical Trial.
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study.
Rieckmann P, Zivadinov R, Boyko A, Selmaj K, Alexander JK, Kadosh S, Rubinchick S, Bernstein-Hanlon E, Stark Y, Ashtamker N, Davis MD, Khan O. Rieckmann P, et al. Among authors: boyko a. Mult Scler J Exp Transl Clin. 2021 Dec 13;7(4):20552173211061550. doi: 10.1177/20552173211061550. eCollection 2021 Oct. Mult Scler J Exp Transl Clin. 2021. PMID: 34925876 Free PMC article.
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
Kieseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, Sheikh SI, Calabresi PA. Kieseier BC, et al. Among authors: boyko aa. Mult Scler. 2015 Jul;21(8):1025-35. doi: 10.1177/1352458514557986. Epub 2014 Nov 28. Mult Scler. 2015. PMID: 25432952 Free PMC article. Clinical Trial.
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, Gouider R, Hacohen Y, Hellwig K, Hemmer B, Kappos L, Ladeira F, Lebrun-Frénay C, Louapre C, Magyari M, Mehling M, Oreja-Guevara C, Pandit L, Papeix C, Piehl F, Portaccio E, Ruiz-Camps I, Selmaj K, Simpson-Yap S, Siva A, Sorensen PS, Sormani MP, Trojano M, Vaknin-Dembinsky A, Vukusic S, Weinshenker B, Wiendl H, Winkelmann A, Zuluaga Rodas MI, Tintoré M, Stankoff B. Tur C, et al. Among authors: boyko a. Mult Scler. 2022 Aug;28(9):1424-1456. doi: 10.1177/13524585211069068. Epub 2022 Feb 23. Mult Scler. 2022. PMID: 35196927 Review.
430 results